Evidence map›Paper›PMID 34232358›Full record

ReviewDer Nervenarzt2021

[The corona pandemic and multiple sclerosis: vaccinations and their implications for patients-Part 2: vaccine technologies].

Tobias Monschein, Tobias Zrzavy, Micha Löbermann, Alexander Winkelmann, Thomas Berger, Paulus Rommer, Hans-Peter Hartung, Uwe K Zettl

Abstract readReview
In one paragraph

Review in Der Nervenarzt, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Tobias MonscheinUniversitätsklinik für Neurologie, Medizinische Universität Wien, Waehringer Guertel 18-20, 1090, Wien, Österreich. tobias.monschein@meduniwien.ac.at.
Tobias ZrzavyUniversitätsklinik für Neurologie, Medizinische Universität Wien, Waehringer Guertel 18-20, 1090, Wien, Österreich.
Micha LöbermannAbteilung für Tropenmedizin und Infektionskrankheiten, Universitätsmedizin Rostock, Rostock, Deutschland.
Alexander WinkelmannKlinik und Poliklinik für Neurologie, Universitätsmedizin Rostock, Rostock, Deutschland.
Thomas BergerUniversitätsklinik für Neurologie, Medizinische Universität Wien, Waehringer Guertel 18-20, 1090, Wien, Österreich.
Paulus RommerUniversitätsklinik für Neurologie, Medizinische Universität Wien, Waehringer Guertel 18-20, 1090, Wien, Österreich.
Hans-Peter HartungUniversitätsklinik für Neurologie, Medizinische Universität Wien, Waehringer Guertel 18-20, 1090, Wien, Österreich. hans-peter.hartung@uni-duesseldorf.de.
Uwe K ZettlKlinik und Poliklinik für Neurologie, Neuroimmunologische Sektion, Universitätsmedizin Rostock, Rostock, Deutschland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Along with the challenges posed by the globally circulating COVID-19 pandemic, there have been some epochal advances in the field of vaccine technologies. In addition to the traditionally used dead, live and protein-based vaccines, vector-based and gene-based vaccines gained enormous attention in the course of this health crisis. The aim of this article is to provide an overview of multiple sclerosis (MS) and vaccination, recent advances in the SARS-CoV‑2 vaccine landscape as well as a detailed discussion of the various vaccine technologies. Finally, clear recommendations in the context of disease-modifying treatment and vaccination in MS are highlighted.

Indexed as

COVID-19Multiple SclerosisVaccinesCOVID-19 VaccinesHumansPandemicsSARS-CoV-2VaccinationCOVID-19 VaccinesVaccinesCOVID-19Gene-basedSARS-CoV-2Vaccine technologiesVector

Identifiers

PMID34232358
PMCPMC8261806

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.